• Explore /
  • Poster
  • / Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.

Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.

Abstract Video & Slides Poster

Authors

null

Scott S. Tykodi

University of Washington, Seattle, WA

Scott S. Tykodi , Lucio N. Gordan , Robert S. Alter , Edward Arrowsmith , Michael Roger Harrison , Ivor John Percent , Rakesh Singal , Peter J. Van Veldhuizen , Daniel J. George , Thomas E. Hutson , Joshua Zhang , Jesus Zoco , Jennifer L. Johansen , Arash Rezazadeh Kalebasty

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02982954

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 309)

DOI

10.1200/JCO.2021.39.6_suppl.309

Abstract #

309

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Hamid Emamekhoo

First Author: Hamid Emamekhoo

First Author: Thomas E. Hutson

First Author: Dirk Schadendorf